Shattuck Labs, Inc. (STTK)
- Previous Close
1.1300 - Open
1.2100 - Bid 1.2900 x 200
- Ask 1.3400 x 100
- Day's Range
1.2000 - 1.4000 - 52 Week Range
1.0700 - 11.7600 - Volume
1,429,512 - Avg. Volume
503,417 - Market Cap (intraday)
68.237M - Beta (5Y Monthly) 1.73
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8500 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
www.shattucklabs.comRecent News: STTK
View More
Performance Overview: STTK
Trailing total returns as of 10/8/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STTK
View MoreValuation Measures
Market Cap
53.69M
Enterprise Value
-47.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.74
Price/Book (mrq)
0.49
Enterprise Value/Revenue
18.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.74%
Return on Equity (ttm)
-68.48%
Revenue (ttm)
4.12M
Net Income Avi to Common (ttm)
-85.28M
Diluted EPS (ttm)
-1.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
105.34M
Total Debt/Equity (mrq)
3.45%
Levered Free Cash Flow (ttm)
-31.85M
Research Analysis: STTK
View MoreCompany Insights: STTK
STTK does not have Company Insights